Updated: Apr 14, 2022
The anti-obesity peptide
Injection SQ fasted: 300 mcg/day
Strong body fat reduction abilities, with no observed side effects
Imitates growth hormone’s ability to regulate fat metabolism
Blocks the transformation of non-fatty foods into body fat storages
Mobilizes stored fat deposits during fasting or exercise
Possible regeneration properties
Reduces stubborn fat, e.g. abdomen
Strong fat burning properties without any side effects
Stimulates lipolysis and inhibits lipogenesis
Does not cause changes in glucose levels & tolerance, insulin sensitivity or IGF-1 levels
HGH-Fragment can be up to 12.5 fold more potent than HGH for fat burning
Buy High-Quality Research AOD-9604 from USA from Vantanex Corp
AOD-9604 is an analogue of growth hormone which can stimulate the pituitary gland to speed up fat metabolism. Developed by Professor Frank Ng in Australia in 1990’s. It is a long ester of hGH fragment 176-191. hGH Fragment 176-191 is a shorter, more potent version of AOD-9604. Meaning that hGH Fragment is ideally used within 10 minutes of vigorous activity, whereas AOD-9604 will continue to provide benefits over a longer period of time.
Mechanism of Action
AOD-9604, (Advanced Obesity Drug), is made of 15 amino acids regions of human Growth Hormone, with an additional tyrosine component which aids in stabilization. It was originally produced as an anti-obesity drug. Injection of AOD-9604 stimulates lipolysis, inhibits lipogenesis and up-regulates fat metabolism which helps burn more calories while in caloric deficit.
no changes in glucose levels observed
no changes in glucose tolerance
no changes in insulin sensitivity
no changes in IGF-1 levels
HGH Fragment 176-191 Research
Fat Burning And Weight Loss
AOD-9604 has shown strong abilities to produce substantial fatloss in mice studies. Heffernan et al., hypothesize that this action is mediated through an increase in production of beta-3 adrenergic receptors (β3-AR or ADRB3), where increased burning of adipose tissue and thermogenesis in skeletal muscle is thought to be correlated with agonist action at this receptor. They confirmed this by testing mice that have been genetically modified to produce no ADRB3 and found no response to lipolytic effects of AOD-9604. They further discovered that AOD-9604 had more effects on obese mice than their lean counterparts. The obese mice experienced nearly 50% reduction in weight gain over 3 weeks. Contradicting this were the mice that started around ideal body weight, which did not experience a reduction in fat. This suggests that there are secondary regulatory pathways for lipolysis that override ADRB3 function when body weight is ideal.
Primarily, the c-terminal end of hGH is responsible for the protein’s hypoglycemic effects, the ability to lower blood sugar. A study by Ng & Bornstein in 1978 tested six different hGH fragments derived from this section of hGH and determined that AOD-9604 is the most effective synthetic derivative of hGH for having hypoglycemic effects. They additionally found a sustained increase in plasma insulin levels. These two factors have made AOD-9604 a possible candidate in treating both prediabetes and type 2 diabetes.
Kwon & Park, 2015, investigated AOD-9604 as a possible treatment for cartilage regneration when combined with hyaluronic acid injections. They studied rabbits receiving both AOD-9604 in isolation and AOD-9604 combined with hyalauronic acid. They found that AOD-9604 injected by itself greatly increased cartilage growth, whereas co-administration produces even great growth effects. Another study confirmed the co-administration to greatly reduce disabilities associated with osteoarthritis, the team speculated this combination may remove the need for osteoarthritis surgeries in some cases.
F. M. Ng and J. Bornstein, “Hyperglycemic action of synthetic C-terminal fragments of human growth hormone,” Am. J. Physiol., vol. 234, no. 5, pp. E521-526, May 1978
M. Heffernan et al., “The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice,” Endocrinology, vol. 142, no. 12, pp. 5182–5189, Dec. 2001
D. R. Kwon and G. Y. Park, “Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model,” Ann. Clin. Lab. Sci., vol. 45, no. 4, pp. 426–432, Jul. 2015
All information found on vantanexcorp.com, and its associated blog is intended for informational and entertainment use only. Vantanex Corp does not provide medical advice. Vantanex Corp tries to provide the most recent and up-to-date research however can make no guarantees this is the case. Vantanex Corp does not condone the use of illegal drugs or the use of drugs for unintended purposes. Before taking any medication, over-the-counter drugs or medication, seek medical advice from a medical professional. No liability will be assumed for the use of these articles, the contained information is not medical advice.
To read more on Vantanex Corp' buying Terms & Conditions, click here.